Literature DB >> 10627139

Identification of a new SCN5A mutation, D1840G, associated with the long QT syndrome. Mutations in brief no. 153. Online.

J Benhorin1, M Goldmit, J W MacCluer, J Blangero, R Goffen, A Leibovitch, A Rahat, Q Wang, A Medina, J Towbin, B Kerem.   

Abstract

The long QT syndrome (LQT) is an inherited cardiac disorder that can cause sudden cardiac death among apparently healthy young individuals due to malignant ventricular arrhythmias. LQT was found to be caused by mutations in four genes LTQ1, LQT2, LQT3 and LQT5, and linkage was reported for an additional locus, LQT4, on chromosome 4q25-27. We have studied a large (n=131) LQT-affected Jewish kindred and identified tight linkage between the LQT-affected status and LQT3 (lod score 6.13, with an estimated recombination fraction of zero). We identified a new point-mutation, A to G substitution at nucleotide 5519 of the SCN5A gene, changing the aspartate 1840 to glycine, D1840G. This is a non-conservative change of an amino acid completely conserved in sodium channels from Molusca to human. The mutation was identified in all affected individuals (n=23), and not identified in all the unaffected family members (n=40), and not in 200 chromosomes of healthy control individuals. The mutation was identified in 3/12 individuals with equivocal phenotype, thus, providing an accurate dignostic tool for all family members. This mutation is currently being used in a cellular electrophysiological model, to characterize the function of the mutated sodium channel in this syndrome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10627139     DOI: 10.1002/(SICI)1098-1004(1998)12:1<72::AID-HUMU19>3.0.CO;2-T

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  8 in total

1.  Crystal structure of the ternary complex of a NaV C-terminal domain, a fibroblast growth factor homologous factor, and calmodulin.

Authors:  Chaojian Wang; Ben C Chung; Haidun Yan; Seok-Yong Lee; Geoffrey S Pitt
Journal:  Structure       Date:  2012-06-14       Impact factor: 5.006

2.  Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.

Authors:  Ehud Chorin; Dan Hu; Charles Antzelevitch; Aviram Hochstadt; Luiz Belardinelli; David Zeltser; Hector Barajas-Martinez; Uri Rozovski; Raphael Rosso; Arnon Adler; Jesaia Benhorin; Sami Viskin
Journal:  Circ Arrhythm Electrophysiol       Date:  2016-10

Review 3.  Fibroblast growth factor homologous factors: evolution, structure, and function.

Authors:  Mitchell Goldfarb
Journal:  Cytokine Growth Factor Rev       Date:  2005-03-23       Impact factor: 7.638

Review 4.  Fibroblast growth factor homologous factors in the heart: a potential locus for cardiac arrhythmias.

Authors:  Eric Q Wei; Adam S Barnett; Geoffrey S Pitt; Jessica A Hennessey
Journal:  Trends Cardiovasc Med       Date:  2011-10       Impact factor: 6.677

5.  Mouse Models of SCN5A-Related Cardiac Arrhythmias.

Authors:  Mickael Derangeon; Jérôme Montnach; Isabelle Baró; Flavien Charpentier
Journal:  Front Physiol       Date:  2012-06-22       Impact factor: 4.566

6.  Calmodulin limits pathogenic Na+ channel persistent current.

Authors:  Haidun Yan; Chaojian Wang; Steven O Marx; Geoffrey S Pitt
Journal:  J Gen Physiol       Date:  2017-01-13       Impact factor: 4.086

7.  Channel openings are necessary but not sufficient for use-dependent block of cardiac Na(+) channels by flecainide: evidence from the analysis of disease-linked mutations.

Authors:  Huajun Liu; Michihiro Tateyama; Colleen E Clancy; Hugues Abriel; Robert S Kass
Journal:  J Gen Physiol       Date:  2002-07       Impact factor: 4.086

Review 8.  Physiological and Pathophysiological Insights of Nav1.4 and Nav1.5 Comparison.

Authors:  Gildas Loussouarn; Damien Sternberg; Sophie Nicole; Céline Marionneau; Francoise Le Bouffant; Gilles Toumaniantz; Julien Barc; Olfat A Malak; Véronique Fressart; Yann Péréon; Isabelle Baró; Flavien Charpentier
Journal:  Front Pharmacol       Date:  2016-01-14       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.